Early mortality in implantable cardioverter defibrillator patients: From randomized controlled trials to real life

Europace

Volumn 11, Issue 6, 2009, Pages 694-696

  Köbe, Julia ^a   Eckardt, Lars ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIAC PATIENT; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATOR; EDITORIAL; HEART VENTRICLE TACHYCARDIA; HUMAN; MORTALITY; PATIENT SAFETY; PRACTICE GUIDELINE; PREDICTION AND FORECASTING; PRIORITY JOURNAL; RISK FACTOR; SUDDEN DEATH; SURVIVAL TIME;

DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; HEART FAILURE; HUMANS; INCIDENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 67651061897     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eup139     Document Type: Editorial

References (11)

1. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH, CIDS studies. Antiarrhythmics vs. implantable defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 2000;21:2071-8.
2. Nanthakumar K, Epstein AE, Kay GN, Plumb VJ, Lee DS. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials. J Am Coll Cardiol 2004;44: 2166-72.
3. Stein KM, Mittal S, Gilliam FR, Gilligan DM, Zhong Q, Kraus SM et al. Predictors of early mortality in implantable cardioverter-defibrillator recipients. Europace 2009; 11:734-40.
4. Parkash R, Stevenson WG, Epstein LM, Maisel WH. Predicting early mortality after implantable defibrillator implantation: a clinical risk score for optimal patient selection. Am Heart J 2006;151:397-403.
5. Marijon E, Trinquart L, Otmani A, Waintraub X, Kacet S, Clémenty J. Competing risk analysis of cause-specific mortality in patients with an implantable cardioverter-defibrillator: The EVADEF cohort study. Am Heart J 2009;157: 391-7.
6. Gradaus R, Block M, Brachmann J, Breithardt G, Huber HG, Jung W. Mortality, morbidity and complications in 3344 patients with implantable cardioverter defi-brillators: results from the German ICD registry EURID. Pacing Clin Electrophysiol 2003;26:1511-8.
7. Stockburger M, Krebs A, Nitardy A, Habedank D, Celebi O, Knaus T. Survival and appropriate device interventions in recipients of cardioverter defibrillators implanted for the primary versus secondary prevention of sudden cardiac death. Pacing Clin Electrophysiol 2009;32:S16-20.
8. Moss AJ. Implantable cardioverter defibrillator therapy: the sickest patients benefit the most. Circulation 2000;101:1638-40.
9. Thibodeau JB, Pillarisetti J, Khumri TM, Jones PG, Main ML. Mortality rates and clinical predictors of reduced survival after cardioverter defibrillator implantation. Am J Cardiol 2008;101:861-4.
10. Bunch TJ, Day JD, Olshansky B, Stolen KQ, Mullin CM. Newly detected atrial fibrillation in patients with an implantable cardioverter-defibrillator is a strong risk marker of increased mortality. Heart Rhythm 2009;6:2-8.
11. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998;32:695- 703.